These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16483768)

  • 1. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.
    Yee SW; Campbell MJ; Simons C
    J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):228-35. PubMed ID: 16483768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
    Swami S; Krishnan AV; Peehl DM; Feldman D
    Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
    Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ
    Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells.
    Swamy N; Chen TC; Peleg S; Dhawan P; Christakos S; Stewart LV; Weigel NL; Mehta RG; Holick MF; Ray R
    Clin Cancer Res; 2004 Dec; 10(23):8018-27. PubMed ID: 15585637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiating effects of nonactive/active vitamin D analogues and ketoconazole in parathyroid cells.
    Segersten U; Björklund P; Hellman P; Akerström G; Westin G
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):399-404. PubMed ID: 17302875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Vitamin D insensitive prostate cancer cells.
    Alagbala AA; Moser MT; Johnson CS; Trump DL; Foster BA
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):712-6. PubMed ID: 17280828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH; Zhao XY; Holloway L; Feldman D
    Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ; Peehl DM; Feldman D
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,25-Dihydroxyvitamin D3 stimulates cyclic vitamin D receptor/retinoid X receptor DNA-binding, co-activator recruitment, and histone acetylation in intact osteoblasts.
    Kim S; Shevde NK; Pike JW
    J Bone Miner Res; 2005 Feb; 20(2):305-17. PubMed ID: 15647825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression.
    Krishnan AV; Peehl DM; Feldman D
    J Cell Biochem; 2003 Feb; 88(2):363-71. PubMed ID: 12520538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of Vitamin D3 metabolism in prostate cancer.
    Lou YR; Qiao S; Talonpoika R; Syvälä H; Tuohimaa P
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):317-25. PubMed ID: 15663995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of 26,26,26,27,27,27-F6-1alpha,25-dihydroxyvitamin D3 by CYP24: species-based difference between humans and rats.
    Sakaki T; Sawada N; Abe D; Komai K; Shiozawa S; Nonaka Y; Nakagawa K; Okano T; Ohta M; Inouye K
    Biochem Pharmacol; 2003 Jun; 65(12):1957-65. PubMed ID: 12787875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.
    Zhuang SH; Burnstein KL
    Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
    Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
    Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of 20-epimer of 1alpha,25-dihydroxyvitamin D3 by CYP24: species-based difference between humans and rats.
    Kusudo T; Sakaki T; Abe D; Fujishima T; Kittaka A; Takayama H; Ohta M; Inouye K
    Biochem Biophys Res Commun; 2003 Oct; 309(4):885-92. PubMed ID: 13679056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.
    Segersten U; Holm PK; Björklund P; Hessman O; Nordgren H; Binderup L; Akerström G; Hellman P; Westin G
    Breast Cancer Res; 2005; 7(6):R980-6. PubMed ID: 16280049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
    Bareis P; Kállay E; Bischof MG; Bises G; Hofer H; Pötzi C; Manhardt T; Bland R; Cross HS
    Exp Cell Res; 2002 Jun; 276(2):320-7. PubMed ID: 12027461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
    Miller GJ; Stapleton GE; Hedlund TE; Moffat KA
    Clin Cancer Res; 1995 Sep; 1(9):997-1003. PubMed ID: 9816072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.